TAG:
analyzer
Sigma-Aldrich, Ivax Diagnostics, i-STAT, Quest Diagnostics, Unilab
By Robert Michel | From the Volume IX No. 8 – June 3, 2002 Issue
SIGMA-ALDRICH SELLS ITS EIA PRODUCT LINE TO IVAX DIAGNOSTICS FOLLOWING ITS DECISION TO EXIT the clinical diagnostics market, Sigma-Aldrich, Inc. has sold its global enzyme immunoassay (EIA) product line to Ivax Diagnostics, Inc., based in Miami, Florida. Th…
“April 22, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
Careside, Inc.’s point-of-care instruments for routine chemistry and hematology are moving into the clinical marketplace. (See TDR, November 22, 1999.) Through January, the company, based in Culver City, California, had placed 73 units, with another 17 on order. Careside 
Court Orders Roche to Pay IGEN $505 Million in Damages
By Robert Michel | From the Volume IX No. 2 – January 28, 2002 Issue
IT WAS A BIG COURT WIN for little IGEN International. On January 10, a jury in federal district court in Maryland decided that IGEN could terminate its licensing agreement with Roche Holding AG. The jury also awarded IGEN a total of $505 million, $105 million in com…
Roche, Digene, Centrex, Labtest.com, Specialty Labs, Tripath Imaging
By Robert Michel | From the Volume VIII No. #15 – November 5, 2001 Issue
ROCHE DIAGNOSTICS POSITIONED TO SERVE PUBLIC HEALTH LABS HEIGHTENED CONCERNS over bioterrorist attacks have accelerated plans within the public health lab sector to acquire state-of-the art diagnostic technology in DNA typing and enzyme immunoassay. Roche Diagnostics has in…
“September 4, 2001 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VIII No. 12 – September 4, 2001 Issue
Here’s early warning: Medicare and Medicaid funding will become high-profile issues during 2002. Numbers just released by the Congressional Budget Office indicate that Medicare spending will increase by 10% during fiscal 2001 over fiscal 2000. Increased provider payments are contri…
“August 13, 2001 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VIII No. 11 – August 13, 2001 Issue
In recent years he’s become an influential “behind the scenes†guy within the lab industry. Now Heywood D. Cochrane, Jr. is joining the Board of Directors at AmeriPath, Inc., based in Riviera Beach, Florida. Most laboratorians know Cochrane from his tour as President and CEO of…
Ortho-Clinical Diagnostics Embraces New Testing Technology
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: Despite a decade of consolidation, competition among the world’s largest diagnostics manufacturers remains intense. In response to this competition, Ortho-Clinical Diagnostics (OCD) is preparing a variety of new products and services for its clinical laboratory customers. I…
IMPATH, AmeriPath, LabOne, MedTox, Genomics Collaborative, PharmChem, CARESIDE, Luminex, Fisher Scientific
By Robert Michel | From the Volume VII No. 12 – August 21, 2000 Issue
EMERGING BUSINESS OPPORTUNITY IN TISSUE BANKS & CANCER DATA EVEN AS THE HEALTHCARE SYSTEM squeezes pathologist incomes in a variety of specific professional services, it opens up business opportunities in other segments of the pathology field. Researchers and pharmaceutical companies wa…
Bio-Reference Labs, CARESIDE, United Healthcare, MetLife, Foundation Health
By Robert Michel | From the Volume VII No. 5 – March 27, 2000 Issue
BIO-REFERENCE LABS MOVES TO START PATIENT-DOCTOR MESSAGING ONE OF THE NATION’S MORE AGGRESSIVE efforts to refocus the clinical laboratory organization can be found at Bio-Reference Laboratories, Inc., located in Elmwood Park, New Jersey. Bio-Reference wants to use its bas…
“State of Lab Industry†Holds Surprises for All
By Robert Michel | From the Volume VII No. 1 – January 3, 2000 Issue
CEO SUMMARY: Say goodbye to several of the trends which shaped the lab industry during the 1990s, such as consolidation and government compliance programs. Although these trends won’t completely disappear, they will be superseded by a number of new transformational influences. During th…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized